Skip to main content
. 2022 Jul 9:10.1111/imm.13535. Online ahead of print. doi: 10.1111/imm.13535

FIGURE 2.

FIGURE 2

SARS‐CoV‐2 ACE2 blocking antibodies in those who received different vaccines at 3 months following full vaccination. ACE2 blocking antibodies were measured by the sVNT assay in 20‐ to 39‐year‐olds who received two doses of Sinopharm (n = 110), AZD1222 (224), Sputnik 1 dose (Sputnik light, n = 50), Sputnik 2 doses (Sputnik V, n = 50) and Moderna 2 doses (n = 48) (a). ACE2 blocking antibodies were also measured in 20‐ to 39‐year olds who received two doses of Sinopharm (n = 41), AZD1222 (26), Sputnik 1 dose (n = 25), Sputnik 2 doses (n = 50) and Moderna 2 doses (n = 48) (b). ACE2 blocking antibodies were also measured in 40‐ to 59‐year‐olds who received two doses of Sinopharm (n = 48), AZD1222 (26), Sputnik 1 dose (n = 25), Sputnik 2 doses (n = 77) and Moderna 2 doses (n = 132) (c). In those >60 years of age, the analysis was carried out in those who received 2 doses of Sinopharm (n = 21), 2 doses of AZD1222 (n = 17) and 2 doses of Moderna (n = 44) (d). The differences in ACE2 blocking antibodies (% of inhibition) between different vaccines were analysed using the Mann–Whitney test. All tests were two‐tailed. The lines indicate the median and the inter quartile range. The positive cut‐off value if shown as a red dotted line. Only P values which indicate a significant difference are shown in the figure.